Literature DB >> 31196575

Trends in surgical complexity and treatment modalities utilized in the management of ovarian cancer in an era of neoadjuvant chemotherapy.

Whitney Horner1, Katherine Peng1, Versha Pleasant1, Melissa Brackmann1, Jasmine Ebott1, Rachel Gutfreund1, Karen McLean1, R Kevin Reynolds1, Shitanshu Uppal2.   

Abstract

OBJECTIVES: To investigate the impact of the increased use of neoadjuvant chemotherapy on the complexity of cytoreductive surgeries for ovarian cancer.
METHODS: Using the National Cancer Database, we performed a retrospective cohort study of women diagnosed between 2004 and 2015 with stage III or IV epithelial ovarian cancer who underwent either primary cytoreductive surgery (PDS) followed by adjuvant chemotherapy, neoadjuvant chemotherapy (NACT) followed by interval debulking surgery. Cases were assigned a surgical complexity category as 1) Inadequate, 2) Low, 3) Moderate and, 4) High complexity. The primary outcome was the trend in surgical complexity over time. Secondary outcomes included temporal trends in treatment modality, perioperative mortality, and survival.
RESULTS: At total of 52,582 (76.3%) underwent PDS and 16,307 (23.7%) underwent NACT. The utilization of NACT increased from 7.7% in 2004 to 27.8% in 2015 (p-trend < 0.001). Patients undergoing moderate complexity surgeries increased from 28.9% to 33.5% and high complexity surgeries from 26.3% to 30% (p-trend < 0.001, for both). Trends in increasing surgical complexity were seen in both NACT and PDS cohorts. This increase in surgical complexity was seen most profoundly at the high-volume centers. Overall 30-day mortality decreased from 3.4% in 2004 to 1.4% in 2015; and 90-day mortality decreased from 7.6% to 4%. During the same time, 5-year survival increased from 39.7% to 49%.
CONCLUSIONS: Increase in the utilization of NACT is associated with decreased 30- and 90-day mortality and increase in five-year survival. Moreover, the overall complexity of ovarian cancer surgery has increased in both PDS and NACT cohorts.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Epithelial ovarian cancer; Neoadjuvant chemotherapy; Surgery

Mesh:

Year:  2019        PMID: 31196575     DOI: 10.1016/j.ygyno.2019.05.023

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  8 in total

1.  National trends in bowel and upper abdominal procedures in ovarian cancer surgery.

Authors:  Joseph A Dottino; Weiguo He; Charlotte C Sun; Hui Zhao; Shuangshuang Fu; Jose Alejandro Rauh-Hain; Rudy S Suidan; Karen H Lu; Sharon H Giordano; Larissa A Meyer
Journal:  Int J Gynecol Cancer       Date:  2020-07-02       Impact factor: 3.437

Review 2.  Primary or Interval Debulking Surgery in Advanced Ovarian Cancer: a Personalized Decision-a Literature Review.

Authors:  Delphine Hudry; Stéphanie Bécourt; Giovanni Scambia; Anna Fagotti
Journal:  Curr Oncol Rep       Date:  2022-08-15       Impact factor: 5.945

3.  Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer.

Authors:  Nicole D Fleming; Shannon N Westin; J Alejandro Rauh-Hain; Pamela T Soliman; Bryan M Fellman; Robert L Coleman; Larissa A Meyer; Aaron Shafer; Lauren P Cobb; Amir Jazaeri; Karen H Lu; Anil K Sood
Journal:  Gynecol Oncol       Date:  2021-04-07       Impact factor: 5.304

Review 4.  Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction.

Authors:  Mackenzie Cummings; Olivia Nicolais; Mark Shahin
Journal:  Diagnostics (Basel)       Date:  2022-04-14

5.  Neoadjuvant chemotherapy for epithelial ovarian cancer in Japan: a JSGO-JSOG joint study.

Authors:  Hiroko Machida; Koji Matsuo; Takayuki Enomoto; Mikio Mikami
Journal:  J Gynecol Oncol       Date:  2019-11       Impact factor: 4.401

6.  Are There Survival Differences Between Women with Equivalent Residual Disease After Interval Cytoreductive Surgery Compared with Primary Cytoreductive Surgery for Advanced Ovarian and Peritoneal Cancer?

Authors:  David Pierce Mysona; Sharad Ghamande; Jin-Xiong She; Lynn Tran; Paul Tran; Bunja J Rungruang; John K Chan; Victoria Bae-Jump; Paola A Gehrig
Journal:  Ann Surg Oncol       Date:  2020-11-05       Impact factor: 5.344

7.  Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy.

Authors:  Derman Basaran; Thomas Boerner; Jessa Suhner; Dib Sassine; Ying Liu; Rachel N Grisham; William P Tew; Ginger J Gardner; Oliver Zivanovic; Yukio Sonoda; Kara Long Roche; Dennis S Chi; Nadeem R Abu-Rustum; Gerald A Soff; Elizabeth L Jewell
Journal:  Gynecol Oncol       Date:  2021-07-24       Impact factor: 5.304

8.  Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.

Authors:  Min Cheng; Howard Hao Lee; Wen-Hsun Chang; Na-Rong Lee; Hsin-Yi Huang; Yi-Jen Chen; Huann-Cheng Horng; Wen-Ling Lee; Peng-Hui Wang
Journal:  Int J Environ Res Public Health       Date:  2019-11-29       Impact factor: 3.390

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.